帕布昔利布中间体2866084-31-3

中文名称2-甲基-2-丙基-4-(6-{[8-环戊基-5-甲基-7-氧代-6-(1-丁氧乙烯基)-7,8-二氢吡啶并[2,3-D]嘧啶-2-基]氨基}-3-吡啶基)-1-哌嗪甲酸中文同义词帕布西利布-中间体7;4-(6-((6-(1-丁氧基乙烯基C-8-环戊基-5-甲基-7-氧代-7,8-二氢吡啶并[2,3-D]嘧啶-2-基C氨基)吡啶-3-基)哌嗪-1-甲酸叔丁酯;2-甲基-2-丙基-4-(6-{[8-环戊基-5-甲基-7-氧代-6-(1-丁氧乙烯基)-7,8-二氢吡啶并[2,3-D]嘧啶-2-基]氨基}-3-吡啶基)-1-哌嗪甲酸;4-(6-(8-环戊基-6-(1-正丁氧基乙烯基)-7,8-二氢-5-甲基-7-氧代吡啶并[2,3-D]嘧啶-2-基氨基)吡啶-3-基)哌嗪-1-羧酸叔丁酯;2-甲基-2-丙基-4-(6-{[8-环戊基-5-甲基-7-氧代-6-(1-丁氧乙烯基)-7,8-二;帕布西利布中间体2;帕布昔利布标准品017;帕布昔利布中间体2英文名称tert-Butyl4-(6-((6-(1-butoxyvinyl)-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate英文同义词PalbociclibImpurity73;Palbociclibimpurity19/Tert-butyl4-(6-((6-(1-butoxyvinyl)-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate;tert-butyl4-(6-(8-cyclopentyl-5-Methyl-7-oxo-6-(1-propoxyvinyl)-7,8-dihydropyrido[2,3-d]pyriMidin-2-ylaMino)pyridin-3-yl)piperazine-1-carboxylate;PalbociclibINT;tert-butyl4-(6-((6-(1-butoxyvinyl)-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate;4-[6-[[6-(1-Butoxyvinyl)-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl]amino]pyridin-3-yl]piperazine-1-carboxylicacidtert-butylester;tert-butyl4-(6-(8-cyclopentyl-5-Methyl-7-oxo-6-(1-propoxyvinyl)-7,8-dihydropyrido[2,3-d]pyriMidin-2;Palbociclib-017CAS号866084-31-3分子式C33H45N7O4分子量603.75EINECS号相关类别对照品-杂质对照品;帕博西尼中间体;杂质对照品;医用中间体;AnticancerMol文件866084-31-3.mol结构式2-甲基-2-丙基-4-(6-{[8-环戊基-5-甲基-7-氧代-6-(1-丁氧乙烯基)-7,8-二氢吡啶并[2,3-D]嘧啶-2-基]氨基}-3-吡啶基)-1-哌嗪甲酸性质沸点764.2±70.0°C(Predicted)密度1.224±0.06g/cm3(Predicted)储存条件2-8°C(protectfromlight)溶解度DMSO（微溶、加热、超声处理）、甲醇（微溶、超声处理）酸度系数(pKa)5.24±0.10(Predicted)形态固体颜色浅黄色稳定性感光InChIKeySCWKOLRZBMGTNT-UHFFFAOYSA-NSMILESN1(C(OC(C)(C)C)=O)CCN(C2=CC=C(NC3=NC=C4C(C)=C(C(OCCCC)=C)C(=O)N(C5CCCC5)C4=N3)N=C2)CC12-甲基-2-丙基-4-(6-{[8-环戊基-5-甲基-7-氧代-6-(1-丁氧乙烯基)-7,8-二氢吡啶并[2,3-D]嘧啶-2-基]氨基}-3-吡啶基)-1-哌嗪甲酸用途与合成方法用途2-甲基-2-丙基-4-(6-{[8-环戊基-5-甲基-7-氧代-6-(1-丁氧乙烯基)-7,8-二氢吡啶并[2,3-D]嘧啶-2-基]氨基}-3-吡啶基)-1-哌嗪甲酸是用于乳腺癌治疗的高选择性CDK4/6可逆抑制剂帕博西林商业开发的中间体。